Investigating the use of intranasal insulin (INI) as a novel treatment option in patients with AD and mild cognitive impairment (MCI) provided clinical evidence of the safety and efficacy of targeting insulin signaling therapeutically in neurodegeneration [131]. The gene discussed is INS; the disease is Cognitive impairment.